Management strategy of infertility in polycystic ovary syndrome

Meng Li , Xiangyan Ruan , Alfred O. Mueck
{"title":"Management strategy of infertility in polycystic ovary syndrome","authors":"Meng Li ,&nbsp;Xiangyan Ruan ,&nbsp;Alfred O. Mueck","doi":"10.1016/j.glohj.2022.03.002","DOIUrl":null,"url":null,"abstract":"<div><p>Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disease in women of reproductive age. PCOS is characterized by ovulatory disruption, which can lead to infertility. Patients with PCOS are also more likely to have poor pregnancy outcomes. For obese women, lifestyle interventions are recommended first, which have general health benefits. For women who have difficulty changing their lifestyle, drugs for the treatment of obesity or bariatric surgery could be considered. Clomiphene citrate is the first-line medication after weight loss that has been utilized in the past. Letrozole is supplanting clomiphene as the best option for ovulation induction for now, particularly in patients with PCOS. Metformin can improve ovulation and pregnancy rates; however, it has minimal effects in terms of raising live birth rates. Second-line therapies include gonadotropins and laparoscopic ovary drilling. In vitro fertilization can be utilized as a third-line treatment for patients with PCOS who have failed ovulation induction therapy or have other infertility factors. In summary, to achieve fertility, patients with PCOS require standardized individualized therapy.</p></div>","PeriodicalId":73164,"journal":{"name":"Global health journal (Amsterdam, Netherlands)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2414644722000240/pdfft?md5=bf145da05e819a1ad9be6bff99a4b857&pid=1-s2.0-S2414644722000240-main.pdf","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global health journal (Amsterdam, Netherlands)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2414644722000240","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disease in women of reproductive age. PCOS is characterized by ovulatory disruption, which can lead to infertility. Patients with PCOS are also more likely to have poor pregnancy outcomes. For obese women, lifestyle interventions are recommended first, which have general health benefits. For women who have difficulty changing their lifestyle, drugs for the treatment of obesity or bariatric surgery could be considered. Clomiphene citrate is the first-line medication after weight loss that has been utilized in the past. Letrozole is supplanting clomiphene as the best option for ovulation induction for now, particularly in patients with PCOS. Metformin can improve ovulation and pregnancy rates; however, it has minimal effects in terms of raising live birth rates. Second-line therapies include gonadotropins and laparoscopic ovary drilling. In vitro fertilization can be utilized as a third-line treatment for patients with PCOS who have failed ovulation induction therapy or have other infertility factors. In summary, to achieve fertility, patients with PCOS require standardized individualized therapy.

多囊卵巢综合征不孕的治疗策略
多囊卵巢综合征(PCOS)是育龄妇女最常见的内分泌代谢疾病。多囊卵巢综合征的特点是排卵中断,这可能导致不孕。多囊卵巢综合征患者也更有可能有不良的妊娠结局。对于肥胖妇女,建议首先进行生活方式干预,这对总体健康有益。对于难以改变生活方式的女性,可以考虑治疗肥胖的药物或减肥手术。枸橼酸克罗米芬是减肥后的一线药物,过去曾被使用过。来曲唑目前已取代克罗米芬成为促排卵的最佳选择,尤其是对多囊卵巢综合征患者。二甲双胍可以提高排卵率和怀孕率;然而,就提高活产率而言,它的效果微乎其微。二线治疗包括促性腺激素和腹腔镜卵巢钻孔。体外受精可作为促排卵治疗失败或有其他不孕因素的PCOS患者的三线治疗。综上所述,为了实现生育,PCOS患者需要标准化的个体化治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Global health journal (Amsterdam, Netherlands)
Global health journal (Amsterdam, Netherlands) Public Health and Health Policy
CiteScore
5.00
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信